Recall of Zicam and Orajel Swabs Due to Fungal Contamination Risk

Certain Zicam and Orajel nasal and teething swabs are being recalled due to potential fungal contamination, posing health risks especially for children and immunocompromised individuals.
In a recent safety alert, U.S. health authorities have announced the nationwide recall of certain nasal and teething swabs manufactured by Church & Dwight Co., Inc., including Zicam Cold Remedy Nasal Swabs, Zicam Nasal AllClear Swabs, and Orajel Baby Teething Swabs. The recall was initiated after the manufacturer identified potential fungal contamination in the cotton components of these products during routine testing.
Consumers are advised to immediately stop using these recalled products, as fungal contamination can pose serious health risks. The infection risk is particularly high for children, individuals with compromised immune systems, or those with existing health conditions. In rare cases, fungal exposure from contaminated swabs can lead to severe infections, including potentially life-threatening blood infections.
The recall covers all lot numbers of the specified products, but other Zicam and Orajel items not listed remain safe. The FDA emphasized that no reported illnesses or injuries have been linked to these products as of now.
Consumers who have purchased affected swabs should visit the official recall website at churchdwightrecall.com or contact the company at (800) 981-4710 for a full refund. The FDA continues to monitor the situation to ensure consumer safety.
This recall highlights the importance of inspecting health products for manufacturing issues and adhering to safety advisories. While most products are safe, fungi-contaminated swabs can cause serious infections, underscoring the need for caution and prompt action when safety warnings are issued.
For further details, the full recall notice is available on the FDA website.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
New Research Finds Mitochondrial Protein Misfolding Contributes to Type 2 Diabetes Progression
Research reveals that misfolded proteins accumulating in mitochondria contribute to beta cell death in type 2 diabetes, offering new therapeutic targets.
Understanding Chronic Venous Insufficiency: Risks, Causes, and Treatment Options
Learn about chronic venous insufficiency, its causes, potential health risks, and available treatment options to maintain healthy veins and prevent complications.
Boehringer Ingelheim Receives U.S. Approval for Innovative Lung Cancer Treatment
Boehringer Ingelheim has received FDA approval for zongertinib, a new oral treatment for HER2-mutant non-small cell lung cancer, offering hope for patients with limited options.